Menu
Oncimmune
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
Healthcare: Diagnostics – cancer
School of Medicine
Profile
Oncimmune has developed a powerful new approach to the early diagnosis of primary cancer, cancer recurrence and the clinical management of cancer.
The technology is based on serum assays that detect auto-antibody formation to known cancer antigens with the clinical utility of early diagnosis of cancer.
This breakthrough is currently applied to lung cancer through the development of a blood test EarlyCDT®, but will be extended to the detection of other common cancers such as breast, colorectal, ovarian and prostate.
The company is based in customised laboratory and office space at Nottingham City Hospital, and began trading on AIM in May 2016.
News and press releases
Our sale of shares represents a significant return on our original investment in Oncimmune and the company is an exemplar of what can be done when a technology is successfully spun out from the University of Nottingham. It has been a pleasure to see Oncimmune grow into a leading early cancer detection company that is already saving lives and is on track to save many more. We look to the future with confidence as the company has the management and strategy in place to deliver value and we are delighted to retain a significant shareholding
Dr Andrew Naylor
Chief executive – Nottingham Technology Ventures
@OncimmuneECDT on Twitter
“It will take months, if not years, to get back to pre-pandemic levels for cancer services.”
@Michelle_CRUK on the spike in undiagnosed cancer as a result of the pandemic and the years-long impact it will have.
Watch in full here: https://torto.se/3q7J5M5
Disruption to cancer services during the pandemic has been a global phenomenon but the important issue is how we tackle it. Looking forward to webinars this month with @LaingBuisson and @spectator to discuss the options. https://www.bbc.co.uk/news/av/world-us-canada-56541223
Cancer services have been hit hard by COVID-19, putting extra strain on people affected by cancer and their families. We’re hugely concerned for people who have symptoms but haven’t come forward or are putting off further tests. 1/3
The system now needs to make sure there is enough capacity in place so that everyone who needs a diagnosis and treatment can get it as quickly as possible. 3/3
"We could face, in this country today, the prospect of #cancer survival reducing for the first time in decades. That's why urgent action is required by the government." @Michelle_CRUK @CR_UK https://www-bbc-co-uk.cdn.ampproject.org/c/s/www.bbc.co.uk/news/amp/newsbeat-56362264 #lungcancer #extratime
There are thousands of people who have been left waiting for a cancer diagnosis and treatment because of the disruption caused by the pandemic. 2/3
We are pleased to see that @NHSEngland has set out the recovery of cancer services as a priority over the next 6 months in the operational planning guidance published this week. 1/3
Super reaction to an over subscribed premium placing by #ONC @OncimmuneECDT can see £3 here in short time. One of the most ignored gems on the market IMO. Well done @Tech_Trender 👏👏
Gallery
